text_1: The in vivo data is still preliminary and other potential roadblocks such as drug resistance have not been examined. 
text_2: The GEM model used in this study retains wild-type Tp53, suggesting that the tumors successfully treated with bortezomib and fasudil might not be as aggressive as those in most NSCLC patients